MiMedx (Nasdaq:MDXG) announced that it appointed Ricci S. Whitlow as its chief operating officer (COO).
Whitlow’s responsibilities include leading manufacturing, supply chain, procurement, quality and regulatory efforts. She joins from Catalent, where she most recently served as president of clinical supply services.
“We are happy to begin 2023 with the addition of Ricci Whitlow to the MiMedx leadership team,” said Todd Newton, MiMedx interim CEO. As our growth goals depend on our ability to manage these changes, we identified the need for a talented and capable operational leader with a unique span of scientific, technology, process and people-leadership expertise. We believe Ricci is this leader.”
Before her time at Catalent, Whitlow held leadership roles across a number of medtech companies. That list includes Optinose, Kinetic Concepts and Johnson & Johnson.
MiMedx, a regenerative medicine company, develops and distributes placental tissue allografts. Whitlow called MiMedx’s portfolio one full of “best-in-class products” and highlighted the company’s “rich product pipeline.” She said she believes the company can help a variety of patients in a variety of ways.
“I am excited to be joining the MiMedx team during this important period in the company’s history,” Whitlow said. “I look forward to working with my colleagues here to grow our operations and tackle the large and growing market opportunities we have in front of us, both today and in the future.”